<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">hepato</journal-id><journal-title-group><journal-title xml:lang="ru">Анналы хирургической гепатологии</journal-title><trans-title-group xml:lang="en"><trans-title>Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-5464</issn><issn pub-type="epub">2408-9524</issn><publisher><publisher-name>НЭИКОН ИСП</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.16931/1995-5464.2016286-92</article-id><article-id custom-type="elpub" pub-id-type="custom">hepato-151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЖЕЛЧНЫЕ ПУТИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BILE DUCTS</subject></subj-group></article-categories><title-group><article-title>МЕТАБОЛИЧЕСКАЯ КОРРЕКЦИЯ ЦЕРЕБРАЛЬНЫХ НАРУШЕНИЙ ПРИ ОБТУРАЦИОННОМ ХОЛЕСТАЗЕ (ЭКСПЕРИМЕНТАЛЬНОЕ ИССЛЕДОВАНИЕ)</article-title><trans-title-group xml:lang="en"><trans-title>METABOLIC CORRECTION OF CEREBRAL DISORDERS IN ACUTE OBSTRUCTIVE CHOLESTASIS (EXPERIMENTAL STUDY)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беляев</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyaev</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Беляев Александр Назарович — доктор мед. наук, профессор, заведующий кафедрой общей хирургии им. Н.И. Атясова </p><p>Для корреспонденции: Беляев Александр Назарович — 430013, г Саранск, ул. Победы, д. 14/5, Республиканская клиническая больница</p></bio><bio xml:lang="en"><p>Belyaev Alexander Nazarovich — Doct. of Med. Sci., Professor, Head of the N.I. Atyasov Chair of General Surgery </p><p>For correspondence: Belyaev Alexander Nazarovich — Republican Clinical Hospital, 14/5, Pobedy str., Saransk, 430013, Russian Federation</p></bio><email xlink:type="simple">belyaevan@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хвостунов</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Khvostunov</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беляев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyaev</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВПО “Мордовский госуниверститет им. Н.П. Огарева”.</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.P. Ogarev Mordovia State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>22</day><month>02</month><year>2018</year></pub-date><volume>21</volume><issue>2</issue><fpage>86</fpage><lpage>92</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Беляев А.Н., Хвостунов С.И., Беляев С.В., Костин С.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Беляев А.Н., Хвостунов С.И., Беляев С.В., Костин С.В.</copyright-holder><copyright-holder xml:lang="en">Belyaev A.N., Khvostunov S.I., Belyaev S.A., Kostin S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://hepato.elpub.ru/jour/article/view/151">https://hepato.elpub.ru/jour/article/view/151</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить функциональные и структурные нарушения в головном мозге при остром обтурационном холестазе, а также возможности их метаболической коррекции.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. На 26 наркотизированных собаках, разделенных на три серии, моделировали острый обту- рационный холестаз путем сдавления общего желчного протока. 1-я группа животных — холестаз без лечения. Во 2-й группе на 3-и сутки осуществляли декомпрессию общего желчного протока и в течение 5 сут вводили 0,9% раствор натрия хлорида 20 мл/кг. В 3-й группе после декомпрессии общего желчного протока дополнительно вводили мексидол 6,5 мг/кг и кортексин 10 мг/кг. В плазме и гомогенате мозга определяли содержание малонового диальдегида и каталазы. Проводили гистологическое исследование ткани мозга при х200 и х400</p></sec><sec><title></title><p>. Результаты. В 1-й группе на 10-е сутки содержание малонового диальдегида в гомогенате мозга было в 4,1 раза больше, уровень каталазы — в 4,3 раза меньше, чем у интактных животных. Структурные изменения характеризовались периваскулярным и перицеллюлярным отеком, редукцией капиллярного русла, вакуолизацией и атрофией нейронов. Во 2-й группе уровень малонового диальдегида в системном кровотоке и гомогенате головного мозга уменьшался в 2,15 и 1,2 раза, а содержание каталазы увеличивалось в 1,36 и 1,22 раза. Сохранялись структурные нарушения мозга. В 3-й группе уровень малонового диальдегида в системном кровотоке и гомогенате головного мозга на 10-е сутки уменьшался в 2,91 и 3,77 раза, а содержание каталазы увеличивалось в 1,57 и 4,76 раза (p &lt; 0,001). Структурная нормализация сопровождалась возрастанием численности микрососудов, устранением вакуолизации и атрофии нейронов, уменьшением отека мозга.</p></sec><sec><title>Заключение</title><p>Заключение. Применение мексидола и кортексина существенно уменьшает процессы свободнорадикального окисления в головном мозге и способствует нормализации структурных нарушений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To research cerebral functional and structural disorders in acute obstructive cholestasis and possibilities of their metabolic correction.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. Acute obstructive cholestasis was simulated by common bile duct compression in 26 anesthetized dogs which were divided into three series.</p><p>The first group included cholestasis dogs without treatment. In the second group common bile duct (CBD) was decompressed in 3 days postoperatively and 0.9% sodium chloride solution (20 ml / kg) was administered for 5 days. In the 3rd group Mexidol® (6.5 mg / kg) and Cortexin® (10 mg / kg) were injected additionally after CBD decompression. In blood plasma and cerebral homogenate malondialdehyde (MDA) and catalase levels were determined. Brain tissue histological investigation was performed with 200x and 400x magnification.</p></sec><sec><title>Results</title><p>Results. In the 1st series on the 10th day MDA and catalase levels in cerebral homogenate were 4.1 times higher and 4.3     times lower than those in control animals. Structural changes were presented by perivascular and pericellular edema, reduction of capillary volume, vacuolization and atrophy of neurons. In the 2nd series there were 2.15-fold and 1.2-fold decrease of MDA in systemic circulation and in cerebral tissue respectively. Catalase activity was increased up to 1.36 and 1.22 times (p &gt; 0.05) accordingly. Cerebral structural disorders were the same. In the 3rd series there were 2.91-fold and 3.77-fold decrease of MDA in systemic circulation and in cerebral homogenate respectively in 10 days postoperatively. Catalase activity was increased up to 1.57 and 4.76 times (p &lt; 0.001) accordingly. Structural normalization was accompanied by increase of microcirculatory volume, elimination of vacuolization and atrophy of neurons, reduction of cerebral edema.</p></sec><sec><title>Conclusion</title><p>Conclusion. Mexidol® and Cortexin® reduce significantly the processes of free-radical oxidation in the brain and contributes to normalization of structural disorders.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>печень</kwd><kwd>желчные протоки</kwd><kwd>обтурационный холестаз</kwd><kwd>головной мозг</kwd><kwd>лечение</kwd><kwd>антиоксиданты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liver</kwd><kwd>bile ducts</kwd><kwd>obstructive cholestasis</kwd><kwd>brain</kwd><kwd>treatment</kwd><kwd>anti-oxidants</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Смолина С.П., Петрова М.М., Шаробаро В.И., Федоров Г.Н., Якубов Д.А. Клиническое течение печеночной энцефалопатии у больных суб- и декомпенсированным алкогольным циррозом печени на фоне применения антиоксидантов. Вестник новых медицинских технологий. Электронное издание. 2013; 1. http://medtsu.tula.ru/VNMT/NewMedTechn.html</mixed-citation><mixed-citation xml:lang="en">Smolirn S.P., Petrova M.M., Sharobaro V.I., Fedorov G.N., Yakubov D.A. The clinical course of hepatic encephalopathy in patients with sub- and decompensated alcoholic liver cirrhosis during treatment with antioxidant. Vestnik novykh meditsinskikh tekhnologiy. Elektronnoye izdaniye. 2013; 1. http://medtsu.tula.ru/VNMT/NewMedTechn.html (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Vaquero J., Chung C., Blei A.T. Brain edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. Ann. Hepatol. 2003; 2 (1): 12—22. PMID: 15094701.</mixed-citation><mixed-citation xml:lang="en">Vaquero J., Chung C., Blei A.T. Brain edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. Ann. Hepatol. 2003; 2 (1): 12—22. PMID: 15094701.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bemeur С., Desjardins P., Butterworth R.F. Evidence for oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy. Metab. Brain Dis. 2010; 25 (1): 3—9. doi: 10.1007/s11011-010-9177-y. PMID: 20195724.</mixed-citation><mixed-citation xml:lang="en">Bemeur С., Desjardins P., Butterworth R.F. Evidence for oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy. Metab. Brain Dis. 2010; 25 (1): 3—9. doi: 10.1007/s11011-010-9177-y. PMID: 20195724.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Desjardins P., Du T., Jiang W., Peng L., Butterworth R.F. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: role of glutamine redefined. Neurochem. Int. 2012; 60 (7): 690—696. doi: 10. 1016/j.neuint.2012.02.001. PMID: 22382077.</mixed-citation><mixed-citation xml:lang="en">Desjardins P., Du T, Jiang W., Peng L., Butterworth R.F Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: role of glutamine redefined. Neurochem. Int. 2012; 60 (7): 690—696. doi: 10.1016/j.neuint.2012.02.001. PMID: 22382077.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Butterworth R.F. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat. Rev. Gastroenterol. Hepatol. 2013; 10 (9): 522—528. doi: 10.1038/nrgastro.2013.99. PMID: 23817325.</mixed-citation><mixed-citation xml:lang="en">Butterworth R.F. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat. Rev. Gastroenterol. Hepatol. 2013; 10 (9): 522—528. doi: 10.1038/nrgastro.2013.99. PMID: 23817325.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rovira A., Alonso J., Cordoba J. MR imaging findings in hepatic encephalopathy. AJNR Am. J. Neuroradiol. 2008; 29 (9): 1612—1621. doi: 10.3174/ajnr.A1139. PMID: 18583413.</mixed-citation><mixed-citation xml:lang="en">Rovira A., Alonso J., Cordoba J. MR imaging findings in hepatic encephalopathy. AJNR Am. J. Neuroradiol. 2008; 29 (9): 1612—1621. doi: 10.3174/ajnr.A1139. PMID: 18583413.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cash WJ., McConville P., McDermott E., McCormick P.A., Callender M.E., McDougall N.I. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM. 2010; 103 (1): 9—16. doi: 10.1093/qjmed/hcp152. PMID: 19903725.</mixed-citation><mixed-citation xml:lang="en">Cash W.J., McConville P., McDermott E., McCormick P.A., Callender M.E., McDougall N.I. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM. 2010; 103 (1): 9—16. doi: 10.1093/qjmed/hcp152. PMID: 19903725.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Полунина Т.Е., Маев И.В. Печеночная энцефалопатия: выбор тактики лечения. Медицинский совет. 2011; 5—6: 101—105.</mixed-citation><mixed-citation xml:lang="en">Polunim T.E., Mayev I.V. Hepatic encephalopathy: treatment strategy selection. Meditsinskiy sovet. 2011; 5—6: 101—105. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева О.Е. Патофизиологические аспекты печеночной энцефалопатии. Вестник неотложной и восстановительной медицины. 2013; 14 (3): 403—411.</mixed-citation><mixed-citation xml:lang="en">Zaitsevа O.E. The pathophysiological aspects of hepatic encephalopathy. Vestnik neotlozhnoy i vosstanovitelnoy meditsiny. 2013; 14 (3): 403—411. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Надинская М.Ю., Подымова С.Д. Заболевания печени и печеночная энцефалопатия. Рецепт. 2006; 4 (48): 132—136.</mixed-citation><mixed-citation xml:lang="en">Nadinskaya M.Yu., Podymova S.D. Liver diseases and hepatic encephalopathy. Recept. 2006; 4 (48): 132—136. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jover-Cobos M., Khetan V., Jalan R. Treatment of hyperammonemia in liver failure. Curr. Opin. Clin. Nutr. Metab. Care. 2014; 17 (1): 105—110. doi: 10.1097/MCO.0000000000000012. PMID: 24281376.</mixed-citation><mixed-citation xml:lang="en">Jover-Cobos M., Khetan V., Jalan R. Treatment of hyper­ammonemia in liver failure. Curr. Opin. Clin. Nutr. Metab. Care. 2014; 17 (1): 105—110. doi: 10.1097/MCO.0000000000000012. PMID: 24281376.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zor'kina A.V., Makedonskaya O.G., Byakin S.P., Fedoseikin I.V., Makhrov V.I. Effects of2-ethyl-6-methyl-3-hydroxypyridine succinate on lipid peroxidation and antioxidant defense in erythrocytes during storage of donor erythrocyte mass. Human Physiology. 2009; 35 (5): 647—649.</mixed-citation><mixed-citation xml:lang="en">Zor'kina A.V., Makedonskaya O.G., Byakin S.P., Fedoseikin I. V., Makhrov V.I. Effects of2-ethyl-6-methyl-3-hydroxypyridine succinate on lipid peroxidation and antioxidant defense in erythrocytes during storage of donor erythrocyte mass. Human Physiology. 2009; 35 (5): 647—649.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Дьяконов М.М., Шабанов П.Д. К вопросу о нейропротек- торном действии пептидных препаратов. Вестник Российской военно-медицинской академии. 2011; 1: 255—258.</mixed-citation><mixed-citation xml:lang="en">D'yakonov M.M., Shabanov P.D. By the question of neuroprotective effect of peptide drugs. Vestnik Rossiyskoy voyenno-meditsinskoy akademii. 2011; 1: 255—258. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Руководства для работы комитетов по этике, проводящих экспертизу биомедицинских исследований; пер. с англ. под научной редакцией О.И. Кубарь, Е.Ю. Бармановой, Е.А. Вольской. Москва — Санкт-Петербург: НЭК РМА, 2000. 32 с.</mixed-citation><mixed-citation xml:lang="en">Rukovodstva dlja raboty komitetov po jetike, provodjashhih jekspertizu biomedicinskih issledovanij [Guidelines for Ethics Committees conducting examination of biomedical researches]; translated from English under the scientific editorship of O.I. Kubar, E.J. Barmans, E.A. Volsky. Moscow — St. Petersburg: NEC PMA, 2000. 32 р. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Королюк М.А., Иванова И.Г., Майорова В.И., Токарев В.Е. Метод определения каталазной активности. Лабораторное дело. 1988; 1: 16—17.</mixed-citation><mixed-citation xml:lang="en">Korolyuk M.A., Ivan^ I.G., Mayorova V.I., Tokarev V.E. Method for determination of catalase activity. Laboratornoye delo. 1988; 1: 16—17. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chroni E., Patsoukis N., Karageorgos N., Konstantinou D., Georgiou C. Brain oxidative stress induced by obstructive jaundice in rats. J. Neuropathol. Exp. Neurol. 2006; 65 (2): 193—198. PMID: 16462210.</mixed-citation><mixed-citation xml:lang="en">Chroni E., Patsoukis N., Karageorgos N., Konstantinou D., Georgiou C. Brain oxidative stress induced by obstructive jaundice in rats. J. Neuropathol. Exp. Neurol. 2006; 65 (2): 193—198. PMID: 16462210.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Булавинцев А.Г., Подшивалова А.К., Буторина Н.В. Чувствительность мозга животных к прооксидантным факторам. Вестник Иркутской государственной сельскохозяйственной академии. 2013; 56: 68—75.</mixed-citation><mixed-citation xml:lang="en">Bulavintsev A.G., Podshivalova A.K., Butorina N.V. The sensitivity of animals brain to pro-oxidant factors. Vestnik Irkutskoy gosudarstvennoy sel'skokhozyaystvennoy akademii. 2013; 56: 68—75. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yu L., Jiang R., Su Q., Yu H., Yang J. Hippocampal neuronal metal ion imbalance related oxidative stress in a rat model of chronic aluminum exposure and neuroprotection of meloxicam. Behav. Brain Funct. 2014; 10: 6. doi: 10.1186/1744-9081-10-6. PMID: 24618126.</mixed-citation><mixed-citation xml:lang="en">Yu L., Jiang R., Su Q., Yu H., Yang J. Hippocampal neuronal metal ion imbalance related oxidative stress in a rat model of chronic aluminum exposure and neuroprotection of meloxicam. Behav. Brain Funct. 2014; 10: 6. doi: 10.1186/1744-9081-10-6. PMID: 24618126.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
